Potential drug-drug interactions in University Hospital Medical Intensive Care Unit patients in Turkey.

OBJECTIVE

Concomitant use of drugs not only enhances the therapeutic effect, but may also lead to undesirable interactions. Drug interactions are frequently seen in intensive care patients. In this study, we aimed to determine the frequency and clinical severity of drug interactions in Medical Intensive Care Unit (MICU) patients.

PATIENTS AND METHODS

The ordered drugs and blood analysis results of 314 patients aged ≥18 years who stayed in the MICU for at least 24 h between January and December 2020 were evaluated. Using the Lexi-Interact online database, clinically significant types of drug interactions, frequently interacting drug/drug groups, and potential adverse reactions were identified.

RESULTS

The average number of drugs in 314 patients was 8.98±5.19. It was determined that polypharmacy was associated with comorbidity and the amount of drug used increased as the number of diagnoses increased. Potential drug-drug interactions were observed in 69.7% of the MICU patients, and it was determined that the amount of interactions increased as the amount of drug used increased. The most common X, D, and C type potential drug-drug interactions, were found between furosemide and salbutamol, enoxaparin and acetylsalicylic acid, ipratropium and potassium chloride, respectively.

CONCLUSIONS

Use of frequently interacting drugs in the treatment of critically MICU patients may lead to potential drug-drug interactions and adverse reactions. Daily monitoring and updating of drug therapy can improve patient's quality of life by preventing or reducing potential drug-drug interactions.